Fast Market Research recommends "Cough, Cold and Allergy (Hay Fever) Remedies in Japan" from Euromonitor International, now available

Boston, MA -- (SBWire) -- 08/28/2014 --Retail value sales of cough, cold and allergy (hay fever) remedies increased by 1% in current terms in 2013. Despite negative performances in combination products, cough remedies, paediatric products and medicated confectionery, strong growth in antihistamines/allergy remedies (systemic) and decongestants contributed to the expansion of the overall category. The performance of the two sub-categories heavily depends on the level of pollen dispersion in spring. Hay fever caused by the dispersion of cedar and cypress pollen every spring is becoming a serious problem in Japan and more and more people suffer from hay fever during the season. The latter two categories grew primarily because of hay fever in spring 2013. According to the ministry of the environment, the amount of pollen dispersed during spring 2013 was 189% greater on average than the previous spring, and 88% larger than usual. Such weather conditions increased the number of hay fever sufferers who demand for antihistamines/allergy remedies (systemic) and decongestants.

View Full Report Details and Table of Contents

Competitive Landscape:

Taisho pharmaceutical Co Ltd maintained the top position in cough, cold and allergy (hay fever) remedies in 2013. The company's brand Pabron led the category in 2013 and was the top brand in most categories where any product under the brand was available. Pabron is also the second largest brand among the Taisho's brands in consumer health in value term. In combination products, LuLu by Daiichi Sankyo ranked second. The company introduced new products from the LuLu brand in August 2013. Stona by Sato Pharmaceutical Co Ltd also showed modest growth. GlaxoSmithKline KK launched a new product from the Contac brand in August 2013, which contains ibuprofen for the first time in the brand's history. The product contains both ibuprofen and dextromethorphan as active ingredients.

Industry Prospects:

Antihistamines/allergy remedies (systemic) is expected to register a flat CAGR at constant 2013 prices over the forecast period. While antihistamines/allergy remedies (systemic) and decongestants have huge potential for growth, combination products, cough remedies and paediatric products are expected to decline over the forecast period, which will make the market static. Although demand for OTC combination products and cough remedies will remain, the wide availability of prescription drugs at affordable prices will continue to prevent growth in these categories. Even though dynamic growth is unlikely, there is expected to be steady demand for pharyngeal preparations because more consumers are aware of the importance of flu prevention.

Retail value sales of dermatologicals in Japan increased by 1% in current terms in 2013. Hair loss treatments remained the largest category in terms of retail value sales. The category's steady growth turned negative in 2012 due to the negative growth of RiUP by Taisho Pharmaceutical Co Ltd, the largest brand in hair loss treatments compared to the significant sales increase of the brand in 2011. The remarkable performance was because of research findings by the Japanese Dermatological Association that certified the effectiveness of the key active ingredient in RiUP. Therefore, compared to 2012, sales of hair loss treatments recovered in 2013. While men's hair loss treatments accounted for the majority of the total sales, women's hair loss treatments expanded its value share in 2013 with several new products launches. In addition to women in middle-age and above, an increasing number of young women in their 30s are using hair loss treatment products for prevention purposes.

Competitive Landscape:

Taisho Pharmaceutical Co Ltd remained the top player in dermatologicals. Its brand RiUP continued to dominate hair loss treatments, with a retail value share of 48% in 2013. The company launched an aerosol version of RiUP in December 2012 to meet the needs of young consumers in their 20s and 30s. Kao Corp's Success ranked second. Compared to RiUP, Success is popular among younger consumers because of its affordable pricing. Other players actively promoted women's hair loss treatments in 2013. Bathclin Corp launched three scalp care sprays for women from its hair loss treatments brand Mouga in February 2013. Lion Corp launched its first women's hair loss treatments product, Fleuria, in June 2013, which is only available online. RiUP also offers a hair loss treatments product for women, RiUP Regenne, although its retail value sales remained low in 2013.

Industry Prospects:

About Fast Market Research
Fast Market Research is a leading distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff is always available to help you find the right research to fit your requirements and your budget.

more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 800-844-8156

Browse all Healthcare research reports at Fast Market Research

You may also be interested in these related reports:

- Cough, Cold and Allergy (Hay Fever) Remedies in Taiwan
- Cough, Cold and Allergy (Hay Fever) Remedies in South Korea
- Cough, Cold and Allergy (Hay Fever) Remedies in Finland
- Cough, Cold and Allergy (Hay Fever) Remedies in Portugal
- Cough, Cold and Allergy (Hay Fever) Remedies in Ireland
- Cough, Cold and Allergy (Hay Fever) Remedies in France
- Cough, Cold and Allergy (Hay Fever) Remedies in Nigeria
- Cough, Cold and Allergy (Hay Fever) Remedies in Slovakia
- Cough, Cold and Allergy (Hay Fever) Remedies in the Czech Republic
- Cough, Cold and Allergy (Hay Fever) Remedies in Saudi Arabia